Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Common Equity: 2017-2025

Historic Common Equity for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to $645.4 million.

  • Protagonist Therapeutics' Common Equity rose 21.34% to $645.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $645.4 million, marking a year-over-year increase of 21.34%. This contributed to the annual value of $675.3 million for FY2024, which is 100.58% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Common Equity stood at $645.4 million for Q3 2025, which was down 3.38% from $668.0 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Common Equity registered a high of $689.1 million during Q1 2025, and its lowest value of $215.6 million during Q4 2022.
  • Moreover, its 3-year median value for Common Equity was $541.3 million (2024), whereas its average is $496.4 million.
  • In the last 5 years, Protagonist Therapeutics' Common Equity skyrocketed by 313.84% in 2021 and then declined by 28.37% in 2023.
  • Quarterly analysis of 5 years shows Protagonist Therapeutics' Common Equity stood at $300.0 million in 2021, then dropped by 28.14% to $215.6 million in 2022, then soared by 56.15% to $336.7 million in 2023, then soared by 100.58% to $675.3 million in 2024, then increased by 21.34% to $645.4 million in 2025.
  • Its Common Equity stands at $645.4 million for Q3 2025, versus $668.0 million for Q2 2025 and $689.1 million for Q1 2025.